Literature DB >> 2820616

Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis.

P S Bunting1, J P Szalai, M Katic.   

Abstract

Angiotensin converting enzyme (ACE) has been measured in 102 biopsy-proven sarcoid patients, 70 patients diagnosed by clinical and radiological methods and 74 nonsarcoid patients as controls. The distributions of the various groups have been examined, and the effects of stage of disease, disease activity and prednisone treatment have been evaluated. Receiver operating characteristic (ROC) curves have been established for ACE, and the appropriateness of various statistical procedures is discussed. We have not discerned any effect of stage of sarcoidosis or of extent of disease activity on ACE values. The ROC curves suggest an upper limit of normal of about 50 U/L for our assay, and a sensitivity of 63% and specificity of 93%, yielding predictive values of 93% for a positive result and 74% for a negative result, with a likelihood ratio of 3.6. The results are discussed in the context of other work on ACE and in relation to the more invasive procedures of bronchoalveolar lavage and Gallium scan.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820616     DOI: 10.1016/s0009-9120(87)80123-6

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  11 in total

1.  Clinical Characteristics and Outcome of Hepatic Sarcoidosis: A Population-Based Study 1976-2013.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Douglas A Simonetto; Eric L Matteson
Journal:  Am J Gastroenterol       Date:  2017-09-05       Impact factor: 10.864

2.  Primary hepatic sarcoidosis presenting with cholestatic liver disease and mimicking primary biliary cholangitis: a case report.

Authors:  Young Joo Park; Hyun Young Woo; Moon Bum Kim; Jihyun Ahn; Jeong Heo
Journal:  J Yeungnam Med Sci       Date:  2021-08-10

3.  Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis.

Authors:  Noriaki Sunaga; Yasuhiko Koga; Yoshimasa Hachisu; Koichi Yamaguchi; Masaki Aikawa; Norimitsu Kasahara; Yosuke Miura; Hiroaki Tsurumaki; Masakiyo Yatomi; Reiko Sakurai; Toshitaka Maeno; Takeshi Hisada
Journal:  Can Respir J       Date:  2022-05-26       Impact factor: 2.130

4.  Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based Study.

Authors:  Patompong Ungprasert; Eva M Carmona; Cynthia S Crowson; Eric L Matteson
Journal:  Lung       Date:  2015-11-13       Impact factor: 2.584

5.  18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.

Authors:  Ruth G Keijsers; Fred J Verzijlbergen; Wim J Oyen; Jules M van den Bosch; Henk J Ruven; Heleen van Velzen-Blad; Jan C Grutters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

6.  Serum ACE Level in Sarcoidosis Patients with Typical and Atypical HRCT Manifestation.

Authors:  Shahram Kahkouee; Katayoon Samadi; Ali Alai; Atefeh Abedini; Lida Rezaiian
Journal:  Pol J Radiol       Date:  2016-09-23

Review 7.  Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis.

Authors:  Patompong Ungprasert; Jay H Ryu; Eric L Matteson
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-08-02

8.  Hepatic Sarcoidosis: Natural History and Management Implications.

Authors:  Mai Sedki; Nicholas Fonseca; Priscila Santiago; Liege Diaz; Monica Garcia-Buitrago; Mehdi Mirsaeidi; Cynthia Levy
Journal:  Front Med (Lausanne)       Date:  2019-10-30

Review 9.  Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments.

Authors:  Rashi Jain; Dhananjay Yadav; Nidhi Puranik; Randeep Guleria; Jun-O Jin
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

10.  Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis.

Authors:  Laura E M Eurelings; Jelle R Miedema; Virgil A S H Dalm; Paul L A van Daele; P Martin van Hagen; Jan A M van Laar; Willem A Dik
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.